The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

BMC Medicine

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Cancer Research

Show all topics

DOI

10.1186/s12916-024-03431-x

License

CC-BY

Other Formats

PDF